Natco Pharma Ltd (NATCOPHARM) is currently trading at 823.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Natco Pharma Limited is a pharmaceutical company specializing in the development, manufacturing, and marketing of niche therapeutic products, focusing on complex generics and high-potency APIs. The company has a strong R&D focus with significant investment in bioequivalence studies and Para-IV filings, enhancing its competitive edge in challenging patents for high-value drugs. Recent acquisitions, such as Dash Pharmaceuticals in the USA and stakes in Adcock Ingram in South Africa, highlight Natco's strategy to diversify and expand its international presence. Strategic partnerships with companies like Viatris and Alvogen facilitate broader market reach and distribution, especially in regulated markets such as the USA and Canada. The company's focus on oncology products and complex generics positions it well within the biotech and pharmaceutical industry, capable of sustaining growth through innovation and market expansion.

Over the past 52 weeks, Natco Pharma Ltd has traded between a low of ₹660.05 and a high of ₹1,340.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Natco Pharma Ltd has a market capitalization of approximately 14,745.22. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Natco Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 9.58 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Natco Pharma Ltd (NATCOPHARM) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 14,745.22 Cr, Natco Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Natco Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Natco Pharma Ltd is 9.58. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Natco Pharma Ltd pays dividends with a current dividend yield of 0.73%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Natco Pharma Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.